Want to see SNDX full AI Analyst Report?
SNDX Stock Chart & Stats
$20.81
-$0.29(-1.39%)
At close: 4:00 PM EDT
$20.81
-$0.29(-1.39%)
Day’s Range― - ―
52-Week Range$12.99 - $25.59
Previous Close$21.22
Volume1.10M
Average Volume (3M)1.97M
Market Cap
$1.78B
Enterprise Value$1.99K
Total Cash (Recent Filing)$547.86M
Total Debt (Recent Filing)$589.38M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Oct 29, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.52
Shares Outstanding89,297,090
10 Day Avg. Volume1,453,657
30 Day Avg. Volume1,971,124
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)28.16
Price to Sales (P/S)10.56
P/FCF Ratio-5.63
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$37.88Price Target Upside82.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.89
Revenue Forecast (FY)$323.49M
Bulls Say, Bears Say
Bulls Say
High Gross Margin And Revenue GrowthSyndax’s commercialization is producing structurally high gross margins (~97.5%) and clear top-line growth (TTM revenue ~ $252M, +16%). High product-level margins mean incremental sales can flow to operating leverage as fixed costs are absorbed, supporting durable improvement in cash generation if growth continues.
Strong Commercial Traction (Revuforj & Niktimvo)Rapid adoption of Revuforj and partner Niktimvo—with double-digit QoQ prescription growth, expanding prescriber accounts and broad formulary coverage—indicates durable commercial capabilities, repeatable patient starts and improving treatment duration that underpin sustainable recurring revenue streams.
Material Cash Runway And Low‑cost Capital AccessWith ~$575M of liquidity including proceeds from low‑coupon convertibles, management says it is funded to execute late‑stage trials and commercial expansion. This capital buffer materially reduces near‑term financing risk and supports delivery of clinical readouts and commercialization over the next 2–6 months.
Bears Say
Severe Cash Burn And Negative Operating Cash FlowSyndax is consuming cash at a very high rate (TTM operating and free cash flow ~ -$220M). Persistent large negative cash flow erodes runway absent sustained revenue growth or further financing, constraining flexibility on R&D, commercialization pace and forcing reliance on external capital over the medium term.
High Leverage, Minimal Equity CushionHeavy debt (~$589M) alongside a near‑depleted equity base (~$15M) leaves limited balance sheet buffer. This elevated leverage increases refinancing and covenant risk, narrows strategic optionality, and raises the probability that future funding will incur dilution or restrictive terms if clinical or commercial performance weakens.
High Expense Guidance And Reliance On Clinical ReadoutsManagement projects substantial 2026 operating spend (~$400M), while major market expansion hinges on multiple near‑term clinical readouts. This combination keeps outcomes highly binary: unfavorable or delayed data would pressure returns on investment and heighten the need for additional capital, making the growth path contingent on trial success.
Syndax Pharmaceuticals News
SNDX FAQ
What was Syndax Pharmaceuticals Inc’s price range in the past 12 months?
Syndax Pharmaceuticals Inc lowest stock price was $12.99 and its highest was $25.59 in the past 12 months.
What is Syndax Pharmaceuticals Inc’s market cap?
Syndax Pharmaceuticals Inc’s market cap is $1.78B.
When is Syndax Pharmaceuticals Inc’s upcoming earnings report date?
Syndax Pharmaceuticals Inc’s upcoming earnings report date is Oct 29, 2026 which is in 70 days.
How were Syndax Pharmaceuticals Inc’s earnings last quarter?
Syndax Pharmaceuticals Inc released its earnings results on Aug 04, 2026. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.448 by -$0.102.
Is Syndax Pharmaceuticals Inc overvalued?
According to Wall Street analysts Syndax Pharmaceuticals Inc’s price is currently Undervalued.
Does Syndax Pharmaceuticals Inc pay dividends?
Syndax Pharmaceuticals Inc does not currently pay dividends.
What is Syndax Pharmaceuticals Inc’s EPS estimate?
Syndax Pharmaceuticals Inc’s EPS estimate is -0.46.
How many shares outstanding does Syndax Pharmaceuticals Inc have?
Syndax Pharmaceuticals Inc has 89,297,090 shares outstanding.
What happened to Syndax Pharmaceuticals Inc’s price movement after its last earnings report?
Syndax Pharmaceuticals Inc reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.448. Following the earnings report the stock price went up 4.403%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in SNDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Syndax Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.88 (82.00% Upside)
$37.88 (82.00% Upside)
Blogger Sentiment
Bullish
SNDX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $152.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
18.03%
Trailing 12-Months
Company Description
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
SNDX Company Deck
SNDX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights robust commercial momentum (double-digit Revuforj growth, strong Niktimvo adoption, expanding prescriber and payer coverage), meaningful R&D progress with multiple near-term data catalysts, and a strong balance sheet that funds execution toward profitability. Offsetting risks include a quarter-of-quarter dip in new patient starts, limited current penetration in the larger NPM1 population, substantial ongoing expense guidance, and dependence on upcoming data readouts to unlock larger indications. Overall the positives (revenue acceleration, elongating treatment duration, pipeline depth, and cash runway) outweigh the near-term operational and clinical-readout risks.View all SNDX earnings summariesSNDX Stock 12 Month Forecast
Average Price Target
$37.88
▲(82.00% Upside)
Technical Analysis
Nektar Therapeutics
―
Xencor
―
Kura Oncology
―
Oric Pharmaceuticals
―
Immunocore Holdings
―
Ownership Overview
1.60% Insiders
15.34% Mutual Funds
52.25% Other Institutional Investors
14.28% Public Companies and Individual Investors